Chemomab Therapeutics Ltd
NASDAQ:CMMB
Intrinsic Value
Chemomab Therapeutics Ltd. operates as a clinical-stage biotech company. [ Read More ]
The intrinsic value of one
CMMB
stock under the Base Case scenario is
1.3928
USD.
Compared to the current market price of 0.6599 USD,
Chemomab Therapeutics Ltd
is
Undervalued by 53%.
Chemomab Therapeutics Ltd's market capitalization is 9.4m USD.
CMMB stock price is 0.6599 USD.
CMMB stock price (0.6599 USD) is 53% less than its Intrinsic Value (1.3928 USD).
CMMB. Open Relative Valuation
CMMB.
CMMB has negative Free Cash Flow for the last twelve months.
CMMB has negative Operating Income for the last twelve months.
CMMB has negative Net Income for the last twelve months.
CMMB's ROE (Return on Equity) has significantly decreased in the last 3 years from -18% to -91%, and is approaching profitability.
CMMB's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -3 054% to -1 529%, and is approaching profitability.
CMMB's ROE (Return on Equity) for the past 12 months is negative and is equal to -91%.
CMMB's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -1 529%.
CMMB has negative three-year average ROE (Return on Equity): -55%. The company is not efficient at transforming stockholders' equity into net income.
CMMB has negative three-year average ROIC (Return on Invested Capital): -1 526%. The company is not efficient at using invested capital to generate operating income.
CMMB's short-term assets (21m USD) exceed its short-term liabilties (5m USD).
CMMB's long-term assets (22m USD) exceed its long-term liabilties (5m USD).
CMMB's D/E (Debt to Equity) is very low and is equal to 0.
CMMB's Altman Z-Score is very low and is equal to -8.76.
Valuation Backtest
Chemomab Therapeutics Ltd
Run backtest to discover the historical profit from buying and selling
CMMB
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Chemomab Therapeutics Ltd
Balance Sheet Decomposition
Chemomab Therapeutics Ltd
| Current Assets | 20.9m |
| Cash & Short-Term Investments | 19.8m |
| Other Current Assets | 1.1m |
| Non-Current Assets | 1.3m |
| PP&E | 695k |
| Other Non-Current Assets | 559k |
| Current Liabilities | 4.8m |
| Accounts Payable | 516k |
| Accrued Liabilities | 4.3m |
| Non-Current Liabilities | 316k |
| Other Non-Current Liabilities | 316k |
Earnings Waterfall
Chemomab Therapeutics Ltd
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-25.5m
USD
|
|
Operating Income
|
-25.5m
USD
|
|
Other Expenses
|
1.2m
USD
|
|
Net Income
|
-24.2m
USD
|
Free Cash Flow Analysis
Chemomab Therapeutics Ltd
What is Free Cash Flow?
CMMB Profitability Score
Profitability Due Diligence
Chemomab Therapeutics Ltd's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Chemomab Therapeutics Ltd's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
CMMB Solvency Score
Solvency Due Diligence
Chemomab Therapeutics Ltd's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Chemomab Therapeutics Ltd's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CMMB Price Targets Summary
Chemomab Therapeutics Ltd
Ownership
CMMB Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
CMMB Price
Chemomab Therapeutics Ltd
| Average Annual Return | -49.24% |
| Standard Deviation of Annual Returns | 39.51% |
| Max Drawdown | -100% |
| Market Capitalization | 9.4m USD |
| Shares Outstanding | 14 204 700 |
| Percentage of Shares Shorted | 1.65% |
Company Profile
Chemomab Therapeutics Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Chemomab Therapeutics Ltd. operates as a clinical-stage biotech company. The firm specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
Contact
IPO
Employees
Officers
The intrinsic value of one
CMMB
stock under the Base Case scenario is
1.3928
USD.
Compared to the current market price of 0.6599 USD,
Chemomab Therapeutics Ltd
is
Undervalued by 53%.
You don't have any saved screeners yet
